REFERENCES
- Ezer U, Gulderen F, Culha V K, Akgul N. Immunological status of thalassemia syndrome. Pediatr Hematol Oncol. 2002; 19: 51–58, [PUBMED], [CSA]
- Ho P J, Thein S L. Gene regulation and deregulation: a β globin perspective. Blood Rev. 2000; 14: 78–93, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hilliard L M, Berkow R L. The thalassemia syndromes. Prim Care Update Obstet Gynecol. 1996; 3: 157–162, [CROSSREF], [CSA]
- Giardina P J, Hilgartner M W. Update on thalassemia. Pediatr Rev. 1992; 13: 55–63, [PUBMED], [CSA]
- Rund D, Rachmilewitz E. New trends in the treatment of β-thalassemia. Crit Rev Oncol Hematol. 2000; 33: 105–118, [PUBMED], [CSA]
- Wanachiwanawin W, Phucharoen J, Pattanapanyasat K, Fucharoen S, Webster H K. Lymphocytes in β-thalassemia/HbE: subpopulations and mitogen responses. Eur J Haematol 1996; 55: 153–157, [CSA]
- Akbar A N, Fitzgerald-Bocarsly P A, De Sousa M, Giardina P J, Hilgartner M W, Grady R W. Decreased natural killer activity in thalassemia major: a possible consequence of iron overload. J Immunol. 1986; 136: 1635–1640, [PUBMED], [CSA]
- Farmakis D, Glakoumis A, Polymeropoulos E, Aessopos A. Pathogenetic aspects of immune deficiency associated with β thalassemia. Med Sci Monit 2003; 9: RA19–RA22, [PUBMED], [CSA]
- Comporti M, Signorini C, Buonocore G, Ciccoli L. Iron release oxidative stress and erythrocyte ageing. Free Radic Biol Med. 2002; 132: 568–576, [CROSSREF], [CSA]
- Klingemann H G. Relevance and potential of natural killer cells in stem cell transplantation. Biol Blood Marrow Transplant 2000; 6: 90–99, [PUBMED], [CROSSREF], [CSA]
- Methenitou G, Maravelias C, Athanaselis S, Dona A, Koutselinis A. Immunomodulative effects of aflatoxins and selenium on human natural killer cells. Vet Hum Toxicol. 2001; 43: 232–234, [PUBMED], [CSA]
- Carr A C, Tijerina T, Frei B. Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem J. 2000; 348: 491–499, [CROSSREF], [CSA]
- Navarro-Alarcon M, Lopez-Martinez M C. Essentially of selenium in the human body: relationship with different diseases. Sci Total Environ. 2000; 249: 347–371, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ferrandez M D, Correa R, Del Rio M, De la Fuente M. Effects in vitro of several antioxidants on the natural killer function of aging mice. Exp Gerontol. 1999; 34: 675–685, [PUBMED], [CROSSREF], [CSA]
- Vojdani A, Namatalla G. Enhancement of human natural killer cytotoxic activity by vitamin C in pure and augmented formulations. J Nutr Environ Med. 1997; 7: 187–195, [CROSSREF], [CSA]
- Vinceti M, Wei E T, Malagoli C, Bergomi M, Vivoli G. Adverse health effects of selenium in humans. Rev Environ Health. 2001; 16: 233–251, [PUBMED], [CSA]
- Wood S M, Beckham C, Yosioka A, Darban H, Watson R R. β-Carotene and selenium supplementation enhances immune response in aged humans. Integrative Med. 2000; 2: 85–92, [CROSSREF], [CSA]
- Huwyler T, Hirt A, Morell A. Effect of ascorbic acid on human natural killer cells. Immunol Lett. 1982; 10: 173–176, [CROSSREF], [CSA]
- Halliwell B. The antioxidant paradox. Lancet. 2000; 355: 1179–1180, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55–63, [CROSSREF], [CSA]
- Schlager S I, Adams A C. Use of dyes and radioisotopic markers in cytotoxicity tests. Methods Enzymol. 1983; 93: 233–245, [PUBMED], [INFOTRIEVE], [CSA]
- Consolini R, Calleri A, Legitimo A, Massei F. Immunological evaluation of patients with beta-thalassemia major. Acta Haematol. 2001; 105: 7–12, [PUBMED], [CROSSREF], [CSA]
- Pattanapanyasat K, Thepthai C, Lamchiagdhase P, et al. Lymphocyte subsets and spesific T-cell immune response in thalassemia. Commun Clin Cytometry 2000; 42: 11–17, [CROSSREF], [CSA]
- Walker E M, Walker S M. Review: effects of iron overload on the immune system. Ann Clin Lab Sci. 2000; 30: 354–365, [PUBMED], [INFOTRIEVE], [CSA]
- Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett. 2003; 90: 103–122, [PUBMED], [CROSSREF], [CSA]
- Bartfay W J, Bartlay E. Selenium and glutathione peroxidase with beta-thalassemia major. Nurs Res. 2001; 50: 178–183, [PUBMED], [CROSSREF], [CSA]
- Winterbourn C C, Kettle A J. Radical-radical reactions of superoxide: a potential route toxicity. Biochem Biophs Res Commun. 2003; 305: 729–736, [CROSSREF], [CSA]
- Meeker H C, Eskew M L, Scheuchenzuber W, Scholz R W, Zarkower A. Antioxidant effects on cell-mediated immunity. J Leukoc Biol. 1985; 38: 451–458, [PUBMED], [CSA]
- Dhur A, Galan P, Hercberg S. Relationship between selenium, immunity and resistance against infection. Comp Biochem Physiol. 1990; 96: 271–280, [CSA]
- Stewart M S, Spallholz J E, Neldner K H, Pence B C. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. Free Radic Biol Med. 1999; 26: 42–48, [PUBMED], [CROSSREF], [CSA]
- Cemeli E, Carder J, Anderson D, et al. Antigenotoxic properties of selenium compounds on potassium dichromate and hydrogen peroxide. Teratog Carcinog Mutagen 2003; 2: 53–67, [PUBMED], [CROSSREF], [CSA]
- Spallholz J E. Free radical generation by selenium compounds and their prooxidant toxicity. Biomed Environ Sci. 1997; 10: 260–270, [PUBMED], [INFOTRIEVE], [CSA]
- Nielsen H B, Secher N H, Kristensen J H, Christensen N J, Espersen K, Pedersen B K. Splenectomy impairs lymphocytosis during maximal exercise. Am J Physiol 1997; 272: R1847–R1852, [PUBMED], [CSA]
- Gerster H. High-dose vitamin C: a risk for persons with high iron stores?. Int J Vit Nutr Res. 1999; 69: 67–82, [CROSSREF], [CSA]
- Vojdani A, Ghoneum M. In vivo effect of ascorbic acid on enhancement of human natural killer cell activity. Nutr Res. 1993; 13: 753–764, [CSA]
- Chen K, Suh J, Carr A C, Marrow J D, Zeind J, Frei B. Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload. Am J Physiol Endocrinol Metab 2000; 279: E1406–E1412, [PUBMED], [CSA]